The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients

BACKGROUND/AIMS: Although daclatasvir with asunaprevir was approved in Japan for interferon ineligible or intolerant patients, patients aged ≥75 years were excluded in the phase III trial. The present study aimed to evaluate the safety and efficacy of this therapy for elderly patients aged ≥75 years...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Gut Liver
Egile Nagusiak: Taki, Shinya, Tamai, Hideyuki, Ida, Yoshiyuki, Shingaki, Naoki, Kawashima, Akira, Shimizu, Ryo, Moribata, Kosaku, Maekita, Takao, Iguchi, Mikitaka, Kato, Jun, Nakao, Taisei, Kitano, Masayuki
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Editorial Office of Gut and Liver 2018
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5753689/
https://ncbi.nlm.nih.gov/pubmed/28798288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5009/gnl17048
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak